OncRef

Clinical Trial: NCT04404283

Brentuximab Vedotin Plus Lenalidomide and Rituximab for the Treatment of Relapsed/Refractory DLBCL

Status:

ACTIVE NOT RECRUITING

Phase:

Phase 3

Lead Sponsor:Seagen, a wholly owned subsidiary of Pfizer
Information Provided By:Seagen Inc.
Last Update Posted:2026-10-21

Study Overview

Brief Summary

Participants in this study will have diffuse large B-cell lymphoma (DLBCL) that has come back or not gotten better with treatment. The trial will study whether brentuximab vedotin plus two drugs works better to treat this type of cancer than the two drugs alone.

Participants will be randomly assigned to get either brentuximab vedotin or placebo. The placebo will look like brentuximab vedotin, but has no medicine in it. Since the study is "blinded," participants and their doctors will not know whether a participant gets brentuximab vedotin or placebo. All participants in the study will get rituximab and lenalidomide. These are drugs that can be used to treat DLBCL.

Official Title

A Randomized, Double-blind, Placebo-Controlled, Active-Comparator, Multicenter, Phase 3 Study of Brentuximab Vedotin or Placebo in Combination With Lenalidomide and Rituximab in Subjects With Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL)

Conditions

Diffuse Large B-cell Lymphoma

Intervention / Treatment

  • Drug: Brentuximab vedotin
  • Drug: Rituximab
  • Drug: Lenalidomide
  • Other: Placebo

Other Study ID Numbers

  • SGN35-031
  • C5691003
  • 2023-503384-41-00
  • 2023

Start Date (Actual)

2020-08-20

Primary Completion Date (Actual)

2026-01-23

Study Completion Date (Estimated)

2026-12-31

Enrollment (Actual)

240

Study Type

Interventional

Phase

Phase 3